EBioMedicine: Scientists discover cell-housekeeping genes or the culprit in triple-negative breast cancer February 02, 2015 Recently, researchers from the UT Southwestern Medical Center in the United States have found a strong correlation between the autophagy gene beclin 1 and triple-negative breast cancer, a study that regulates the natural cell cycle of the body. Published in the international magazine EbioMedicine . Researcher Beth Levine said that we have identified a novel approach in malignant triple-negative breast cancer. These data suggest that a decrease in beclin 1 gene activity leads to lower survival rates in breast cancer and patients, and therefore increases Targeted therapy with beclin 1 gene activity may be effective in treating triple-negative breast cancer. Triple-negative breast cancer accounts for 10% to 20% of breast cancer. Triple-negative breast cancer is named because it lacks estrogen and progesterone receptors in breast cancer cells, and there is no excess human growth factor receptor on the surface of cancer cells. 2 (HER2), current chemotherapy is not effective in treating triple-negative breast cancer. In the article, the researchers said that when the expression of beclin 1 gene is reduced, the risk of triple-negative breast cancer is increased by 35 times. The researchers analyzed the expression levels of beclin 1 and BRCA1 in 3,057 breast cancer individuals. The BRCA1 gene is Genes associated with hereditary breast cancer, the researchers found that about 35% of breast cancer individuals are deficient in beclin 1 and BRCA1 genes, and the low expression of beclin 1 gene is directly related to the poor clinical outcome of the individual. Compared with cancer patients with high expression of beclin 1 gene, breast cancer patients with lower expression of beclin 1 gene will increase the risk of death by 67%; therefore, the increase of beclin 1 gene expression activity may be a new target for the treatment of triple-negative breast cancer. At present, many drugs that can increase the activity of beclin 1 gene are used to treat other cancers, including four types of drugs: inhibitors of beclin 1 or BCL-2 binding, protein kinase B (AKT), epidermal growth factor receptor ( EGFR), HER2. The final researcher, Levine, said that our study provides a more in-depth study to see if the upregulation of beclin 1 can effectively save the lifespan of breast cancer patients; we are currently investigating autophagy, cancer, and aging. In the process of infection and related genes in the process of neurodegenerative diseases, we hope to develop new therapies for cancer treatment by using computer analysis and clinical data. Original link: http://news.bioon.com/article/6665499.html Yancheng Rongtai Labware Co.,Ltd , https://www.shtestlab.com